On Monday the United States regulator granted fast-track approval for the drug aducanumab, which will be marketed in the US as Aduhelm by biotechnology company Biogen.
The active ingredient in the drug, the aducanumab antibody, was discovered by researchers at the University of Zurich’s Institute for Regenerative Medicine and the Zurich-based biopharmaceutical company Neurimmune.
Alzheimer’s is the most common form of dementia in the elderly, affecting tens of millions of people worldwideExternal link. It is caused by deposits of proteins, called amyloid plaques, in the brain that accumulate over years and damage neurons. It results in progressive memory loss and impairment of learning, orientation, language and planning abilities.
Zurich researchers identified antibodies that neutralise amyloids and “ultimately discovered the substance called aducanumab”, the University of Zurich said in a press release on Monday eveningExternal link.
Neurimmune, a spin-off company from the university founded by two of its professors, says on its websiteExternal link that it is collaborating with Biogen and Japanese company Eisai to develop the drug.
The decision by the US Food and Drug Administration (FDA) to grant the treatment “accelerated approval” has met with some criticism. Drugs can be fast-tracked “to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need”, says the FDAExternal link.
The FDA concluded that the likely benefits of the treatment outweighed the risks of applying a therapy with limited and inconsistent clinical trial data.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
Consumer prices picked up again in June in Switzerland, after briefly dipping into negative territory the previous month.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Alzheimer’s vaccine candidate shows promise
This content was published on
The results, published in the latest edition of the Journal of Neuroscience, show that the vaccine impedes the appearance of a protein that is a hallmark of the disease. Beta-amyloid proteins amass in the brain when a person suffers from Alzheimer’s. These so-called plaques are considered to be a typical indicator of the disease, although…
This content was published on
There are far more people with dementia in Switzerland than previously thought – and the number is expected to double over the next 25 years.
This content was published on
But the scientists warn it could be years and plenty of money before any potential application appears on the drug market. It is believed to be the first time that a potent agent against Alzheimer’s has been extracted from a type of cyanobacteria commonly known as ‘pond scum.’ The new compound, nostocarboline, was isolated by…
Study points to shortcomings in dementia diagnosis
This content was published on
The report by the Swiss Alzheimer’s Association also warns that three-quarters of those with the mental disorder are not receiving the proper treatment. The association described the results of the study, published ahead of World Alzheimer’s Day on Tuesday, as “alarming”. It also warned that Switzerland’s health system would face an “enormous challenge” in the…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.